BPC-157 TB-500 dosage, as studied — not as prescribed

Research dosing context for the BPC-157 / TB-500 blend

BPC-157 TB-500 dosage has no validated value for the blend. The figures below come from single-compound animal studies and describe what was administered to which species by which route — they are not human guidance and do not translate to a blend dose. The framing throughout this panel is deliberate: "studied at X in [species] by [route]," never "take X."

The BPC-157 channel, in rodent models, is commonly expressed per body weight, frequently around 10 microg/kg and 10 ng/kg ^[1]. Expressing a dose per kilogram of body weight is how animal pharmacology works, and it is precisely why those numbers cannot be lifted into a fixed human milligram amount. The TB-500 / Thymosin Beta-4 channel spans a far wider range in the underlying studies — for example a rat embolic-stroke dose-response study used 2-18 mg/kg intraperitoneal, with the highest dose giving no benefit (higher was not better), and a six-month mdx muscular-dystrophy study used 150 microg twice weekly intraperitoneally ^[4]. That non-monotonic result is the single most useful caution on this page, because it directly contradicts the loading logic behind many community blend protocols.

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated in Phase 1 work ^[4]. Commercial vials commonly pair fixed combined masses (e.g. ~10 mg + ~10 mg), but no peer-reviewed combination dose-finding study exists, and the fixed-mass label is a packaging convention, not a validated dose ^[1].

Routes studied for the Wolverine blend constituents

The routes the research used are not the routes the community uses, and the distinction matters for anyone reading vendor protocols or searching for a "wolverine injection" schedule. The underlying rodent efficacy studies for both peptides were predominantly intraperitoneal; human Phase 1 data for full-length Thymosin Beta-4 used intravenous routes ^[4]. Subcutaneous and intramuscular administration are the predominant research-community routes for the blend, but they do not come from controlled human efficacy trials. There is no validated injection frequency for the blend; the rodent studies dosed on study-specific schedules — for example 150 microg twice weekly in one six-month mouse study ^[4].